Vaginal infections represent a unique health challenge for women, with one billion women worldwide troubled by vaginal infections and UTIs annually⁽⁷⁾. Discomforting symptoms leading to frequent hospital visits, the estimated annual global economic burden of the treatment of vaginal infections costs US $4.8 billion⁽⁵⁾, affecting not merely physical health but also emotional and social well-being of women such as worry about the symptoms and suffering from lack of confidence in social interaction. The most common treatment for vaginal infections to date is antifungal drugs. However, these drugs come with drawbacks such as increased recurrence rate and drug resistance.

The healthy vagina is primarily colonized with the genus Lactobacillus, which is the most abundant bacteria, accounting for more than 95% of the microorganisms in the vagina. Lactobacilli serve as a gatekeeper to maintain vaginal health by decomposing the glycogen into lactic acid and hydrogen peroxide (H₂O₂), acidify the vagina environment with lactic acid. In addition, lactobacilli adhere to the vaginal epithelial cells and inhibit the growth of pathogens, thereby helps maintain the balance of the vaginal flora and improve vaginal health⁽¹⁾. Decreased amount of lactobacilli in the vaginal microbiota is associated with increased disease risk.

As women continue to seek ways to improve their well-being, the global women's healthcare market is rising sharply, the market was worth USD 31.04 billion in 2019 and is expected to reach USD 45.31 billion in 2027⁽³⁾. Furthermore, increasing numbers of women are seeking science-backed natural solutions for supporting their everyday well-being. In light of this, probiotics could present as the optimal solution.
 
As science continues to shed light on the critical role of probiotics in wellbeing, probiotic consumption continues to grow, the global probiotics market is projected to be worth USD 91.1 billion by 2026, growing at a CAGR of 8.3%⁽⁶⁾. Furthermore, study suggests that probiotics could even substitute pharmaceutical agents⁽⁶⁾. However, today’s consumers are more informed and connected than ever before. Study suggests that 39% of global consumers are more likely buy a healthy lifestyle product if its claims are based on scientific data⁽⁴⁾. Therefore, incorporating science-backed probiotics is the key to differentiation and staying ahead of competition in women's healthcare market.

With longstanding expertise in probiotics research, Synbio Tech. has developed an innovative solution to help women battling with vaginal candidiasis (VC). SynForU™-HerCare is clinically validated probiotics incorporating six patented Lactobacilli strains (LA25, LDL114, LP115, LF26, LRH10, LPC12). The study published in the Journal of Applied Microbiology investigated the effects of SynForU™-HerCare in 78 pregnant women with VC⁽²⁾. The results show that SynForU™-HerCare not only improves the physical health aspect, it also improves the emotional well-being of the participants⁽²⁾. SynForU™-HerCare shows:

With robust scientific evidences, SynForU™-HerCare helps the brands to stand out in the women's healthcare market while empowering women by providing holistic support to their everyday well-being. SynForU™-HerCare is our commitment to providing long-term care for women around the globe, thereby making a difference in their life.